Glycemic control with metformin or insulin therapy in adolescents with type 2 diabetes mellitus
Abstract
BACKGROUND: Only metformin and insulin are approved by the FDA for adolescents.
OBJECTIVE: To study the efficacy of insulin versus metformin in adolescents with type 2 diabetes mellitus (DM2) and examine whether psychosocial factors affect therapeutic efficacy.
METHODS: Phase I involved a retrospective examination of the medical records of 18 adolescents with DM2. Glycemic control was evaluated by mean HbA1c. We tested for relationships between glycemic control and BMI, number of outpatient visits per year, and self-reported compliance. Phase II employed a pilot questionnaire.
RESULTS: Glycemic control deteriorated when therapy was changed from insulin (HbA1c, 5.0+/-2.6% [SD]) to metformin (8.4+/-2.9%; p <0.05). Self-reported compliance positively predicted glycemic control (p <0.005) and inversely correlated with degree of weight loss (p <0.05). Pilot questionnaire data suggested that patients may perceive their DM as less serious when treated with metformin.
CONCLUSIONS: Metformin was often ineffective in our adolescents with DM2 and compliance was a major factor. Altered perception of the seriousness of their DM may have influenced adherence to therapy.
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 18 participants or records.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.